ࡱ> #` bjbj 1V ;44445DG<r^7:8:8:8:8999{}}}}}}$hQj:99j:j::8:8^D^D^Dj::8:8{^Dj:{^D^D.sH7:8R7 pnQL84|;@7D 0<<ʧv<ʧ7ʧ79La96^D9,9999TD 999<j:j:j:j:GGGxuGGGx   MODULE L PULMONARY FUNCTION MEASUREMENTS Definition of Terms C-BABE - Obstructive Lung Diseases Chronic Obstructive Pulmonary Disease (COPD) or Chronic Obstructive Lung Disease (COLD) DLCO Effort Dependent Forced Expiratory Maneuver Effort Independent Forced Expiratory Maneuver Expiratory Reserve Volume Forced Vital Capacity Flow-Volume Curve (Loop) Forced Expiratory Volume Timed (FEVT) Forced Expiratory Volume 0.5 seconds (FEV 0.5) Forced Expiratory Volume 1.0 second (FEV 1.0) Forced Expiratory Volume 2.0 seconds (FEV 2.0) Forced Expiratory Volume 3.0 seconds (FEV 3.0) Forced Expiratory Volume 1 second/Forced Vital Capacity Ratio (FEV1/FVC) Forced Expiratory Flow 200-1200 (FEF 200 1200) Forced Expiratory Flow 25 75% (FEF 25 75%) Inspiratory Capacity Inspiratory Reserve Volume Maximum Voluntary Ventilation (MVV) Peak Expiratory Flowrate (PEFR) Residual Volume Restrictive Lung Disease RV/TLC% Spirogram Tidal Volume Total Lung Capacity Vital Capacity Lung Volumes The total amount of air that the lungs can hold is divided into four separate lung volumes Tidal Volume The volume of air normally moved into or out of the lungs in one quiet breath 500 mL (5-8 mL/kg) Inspiratory Reserve Volume The maximum volume of air that can be inhaled after a normal tidal volume inhalation 3100 mL Expiratory Reserve Volume The maximum volume of air that can be exhaled after a normal tidal volume exhalation 1200 mL Residual Volume The amount of air remaining in the lungs after a maximal exhalation 1200 mL Lung Capacities Lung Capacities are formed from two or more lung volumes Vital Capacity (VC) The maximum volume of air that can be exhaled after a maximal inspiration (IRV + Vt + ERV) Slow Vital Capacity (SVC) exhalation is performed slowly Forced Vital Capacity (FVC) exhalation is performed as rapidly as possible. SVC = FVC ATS standards: SVC should be within 5% of FVC Normal Value: 4800 mL Inspiratory Capacity (IC) The maximum volume of air that can be inhaled after a normal exhalation. Vt + IRV 3600 mL Functional Residual Capacity (FRC) The volume of air remaining in the lungs after a normal exhalation. (ERV + RV) 2400 mL Total Lung Capacity (TLC) The maximum amount of air in the lungs IC + FRC 6,000 mL Residual volume/Total Lung Capacity (RV/TLC x 100) Normal value: 20% Measurements of Volumes and Capacities Volume/Capacities measured with simple spirometry Vt IRV ERV VC IC Volumes/Capacities that cannot be measured directly RV FRC TLC These three volumes/capacities can only be measured indirectly by the following tests Nitrogen Washout He dilution Body Plethysmography Most accurate for patients with COPD. Actually measures Thoracic Gas Volume (TGV) Obstructive Diseases Obstructive lung disorders are the C-BABE diseases Asthma Bronchieactasis Chronic bronchitis Emphysema Cystic fibrosis Also caused by Airway Obstructions Lung Tumors/Neoplasms Foreign bodies Goiters Vocal cord dysfunction Croup/epiglottitis Interpretation Obstructive lung disorders result in: A reduction in flowrates and FEVT/FVC (% ) An increase in the RV, FRC, TLC, RV/TLC ratio A FVC that is less than the VC or SVC. Restrictive Diseases Interstitial Lung Diseases Idiopathic fibrosis Pneumoconioses Siderosis Iron dust Found in welders/miners Stannosis Tin dust Found in metal worker Baritosis Barium Found in miners Silicosis Silica dust Found in sandblasters, brick makers, coal miners Asbestosis Asbestos dust Brake/clutch manufacturers Shipbuilders Used as an insulator. Exposure may be do occupation of an old building Talcosis Talc dust Ceramics or cosmetic maker Berylliosis Beryllium Found in alloy makers, electronic tube makers (rare) Coal workers pneumoconiosis Coal dust Coal miner Sarcoidosis Diseases of chest wall and pleura Pleurisy Kyphoscoliosis/scoliosis Pleural effusions Pneumothorax Obesity Neuromuscular Disorders Guillain Barr Myasthenia Gravis ALS, or Lou Gehrigs disease Diaphragmatic paralysis CHF Restrictive lung disorders result in decreased VC, IC, RV, FRC, Vt and TLC Flowrate Measurements (Evaluate on Volume-Time Curve or Flow-Volume Loop) Forced Expiratory Volume Timed (FEVT) This is the maximum volume of gas that can be exhaled over a specific time period. This measurement is obtained from the FVC. FEV 0.5 - Forced expiratory volume in 0.5 seconds FEV1 - Forced expiratory volume in 1 second FEV2 Forced expiratory volume in 2 seconds FEV3 Forced expiratory volume in 3 seconds With obstructive lung disease, the FEVt measurements are decreased Forced Expiratory Volume Timed/Forced Vital Capacity Ratio This is the ratio of the volume of gas that can be forcefully exhaled in a certain time period compared to the FVC FEV 0.5% - Forced expiratory volume in 0.5 seconds/FVC FEV 1% - Forced expiratory volume in 1 second/FVC FEV 2% - Forced expiratory volume in 2 seconds/FVC FEV 3% - Forced expiratory volume in 3 seconds/FVC Normal Values: FEV0.5% is 60% FEV1% is 83% (minimum acceptable value is 75%) FEV2% is 94% FEV3% is 97% The FEVt/FVC is decreased in obstructive lung disorders and is normal in restrictive lung disorders Forced Expiratory Flowrate 200 1200 (FEF 200-1200) This is the average rate of airflow between 200 mL and 1200 mL of the FVC. This is a measurement of the integrity of the large airways. Normal value for the healthy male is 8 L/sec (480 L/min). This measurement will be decreased in obstructive lung disease. Forced Expiratory Flowrate 25-75% (FEF 25-75%) Also known as the Maximal Mid-expiratory Flowrate. This is the average flowrate during the middle 50% of an FVC measurement This reflects the status of the medium to small airways. Normal value for the healthy lung is 4 5 L/sec. This measurement will be decreased in obstructive lung disease. Peak Expiratory Flowrate (PEFR) The maximum flow rate that can be achieved. Also known as the peak flow rate. This measurement is obtained from the FVC & represents airflow in the large airways. Normal values for a healthy male is 10 L/sec or 600 L/min and for a female 7.5 L/sec or 450 L/min. PEFR are often measured before and after giving a bronchodilator to the asthmatic patient. Maximum Voluntary Ventilation (MVV) This is the largest volume of gas that can be breathed voluntarily in an out of the lungs in 1 minute. The breath should be larger than the Vt but less than the VC The patient only performs the test for 12 or 15 seconds and the volume is extrapolated over 1 min. The MVV is a general test that evaluates the performance of the respiratory muscles, compliance of the lung and thorax, ventilatory drive and airway resistance. The average MVV for the healthy male is 170 L/min (range of 150 200 L/min) The MVV will be decreased in obstructive lung disease, neuromuscular disease and poor effort Calculated MVV = FEV1.0 x 35. Criteria for acceptability: Two acceptable maneuvers must be obtained within 10%. Flow-Volume Curves (Loops) Graphic Presentation The F-V loop is a graphic presentation of a forced vital capacity (FVC) maneuver followed by a forced inspiratory volume (FIV) maneuver. When the FVC and FIV are plotted together, the graphic illustration by the two curves is called the flow volume loop. Measurements Peak Expiratory Flowrate (PEFR) Peak Inspiratory Flowrate (PIFR) Forced Vital Capacity (FVC) Forced Expiratory Flow 25%, 50%, 75% Interpretation of the F-V Loop COPD patients will display a scooped out appearance. Restrictive patients will display a narrow curve with decreased FVC. Factors Influencing Flow Rates Effort Dependent During the first 30% of the forced vital capacity maneuver, the maximum peak flowrate is dependent on the amount of muscular effort exerted by the individual. Therefore the first 30% of a FVC is called effort dependent portion of the curve. Effort Independent The flowrate during the last 70% of the FVC is effort independent. This means that once a maximum flow rate has been attained, the flow rate cannot be increased by further muscular effort. Lung Volumes The lung volume at which a patient initiates a forced expiratory maneuver also influences the maximum flow rate. As lung volumes decline, flow also declines. Diffusion Capacity of Carbon Monoxide (DLCO) Carbon Monoxide Single-Breath Technique/Steady State Technique This test is used to measure the amount of CO that moves across the alveolar-capillary membrane. CO has an affinity for Hb that is about 210 times greater than that of oxygen. Steady State and Single Breath DLCO tests Values are measured in ml/min/mm Hg. The DLCO may increase 3 times in a normal individual during exercise. The DLCO is decreased in emphysema. When interpreting a PFT, if you determine the patient has an obstructive lung disease, then measure DLCO to determine if the obstruction to airflow is due to emphysema. DLCO can also be decreased in restrictive lung disease. Pulmonary Function Interpretation Pulmonary Function Tests are used to evaluate for: Obstructive Diseases C Cystic Fibrosis B Bronchiectasis A Asthma B Bronchitis E Emphysema Croup & Epiglottitis Foreign Bodies Tumors in the airway Restrictive Diseases Diffusion Defects Interpretation of Obstructive Disease FVC can be decreased or normal. SVC will be greater than the FVC . Decreased Flowrates FEF200 1200 FEF25 75% PEFR FEVT/FVC will be decreased FEV1.0 is also reduced and used to stage disease process. Increased RV, FRC, TLC. If the FVC cannot be completed in 3 seconds, obstructive disease is present. **If a patient is diagnosed with obstructive disease, a Pre and Post Bronchodilator Test should be ordered to determine if a patient is responsive to bronchodilators. Interpretation of Restrictive Lung Diseases **Decreased Volumes (( FVC and TLC) Flowrates may be decreased because the FVC is decreased. BUT: ** FEVT/FVC is normal Combined Obstructive and Restrictive Disorders Decreased Flowrates Decreased Volumes Diffusion Defect DLCO Diffusion Defects can occur in Obstructive and Restrictive Diseases The only Obstructive disease that results in a diffusion defect is emphysema. Classification of Interpretation 80 120% of predicted = normal PFT 65 79% of predicted = mild obstructive or restrictive disease 50 64% of predicted = moderate obstructive or restrictive disease 35 - 49% of predicted = severe obstructive or restrictive less than 35% of predicted = very severe Instrumentation The criterion for pulmonary function testing is based on the recommendations of the American Thoracic Society (ATS). They published standards in 1979, 1987, 1995 Volume Displacing Spirometers (measure volume and time) Types of: Water Seal (Collins and Stead-Wells) Gold Standard because it is most accurate Uses a Kymograph as a recording device (a rotating drum on which a maneuver is recorded on graph paper) Developed by John Hutchinson in 1850s Dry Rolling Seal (horizontal piston) Bellows type spirometer Diaphragm spirometer Advantages Directly measure volume Low cost Ease of operation Disadvantages LEAKS Large and bulky Water in water seal needs changing Without microprocessor/computer, manual calculations are needed Flow Sensing Spirometers (Pneumotachometers) Mechanism Flow sensing spirometers use various physical principles to produce a signal proportional to gas flow. This signal is then integrated to measure volume in addition to flow. Integration is a process in which flow (Volume/Time) is divided into a large number of small intervals (time) and volume from each interval is determined. RCP use pneumotachs in respirometers, mechanical ventilators, incentive spirometers, pulmonary function equipment Types Pneumotachometers (Pressure Differential Flow Sensors) Uses a pressure change caused by a resistive element to calculate flow  EMBED Equation.3  Any (/( in P will affect flow Resistance needs to be kept constant Multiple types Fleisch Type (uses a bundle of capillary tubes as resistance) Screen Type (fiber and metal) Ceramic Type Turbines or Tubinometers (do not use integration) Simplest type of flow sensing device is the turbine or respirometer Vane connected to a series of precision gears Gas flow causes the vane to rotate Wright respirometer (measures flow between 3 and 300 L/min Gas sterilized Heated Wire Flow Sensors (hot wire anemometer or thermistors) Based on the cooling effect of gas flow; a heated element usually a thin platinum wire is situated in a laminar flow tube. As gas flows past the wire a temperature drop occurs so that more current must be supplied to maintain the temperature. Sonic Devices (uses sound waves) Ultrasonic Flow Sensors (sound waves) Vortex (struts are used to create turbulent flow or vortices) this principle is used in Servo i Advantages Smaller and usually more portable Computerized; no manual calculations Bidirectional devices provide flow volume loop capability Disadvantages More knowledge needed to operate Frequent calibration Moisture and secretions can cause inaccurate readings Gas composition can affect results May not sense high or low flows Flow Sensing Peak Flow Meters More important to be precise than accurate Repeated measurements should be reproducible (valid) within 5% or 10 L/min whichever is greater Tend to underestimate flowrate as altitude increases Spirometer Calibration Spirometers should be calibrated every day to reduce likelihood of error. Volume displacement spirometers should also be leak tested A Super Syringe is used to calibrate spirometers. The spirometer volume should be equal to the syringe volume by +/- 3%. If using a 3 liter syringe the acceptable range of volume would be 2.91 to 3.09 liters If a spirometer cannot measure the calibration syringe volume within +/-3%, do not use it until it is serviced or repaired. Characteristics of Volume and Flow Measuring Devices Capacity: How much an instrument can measure; range of limits of measurement. Volume Spirometers: How large or how small a volume it can measure. Flow Spirometers: How fast or slow a flow rate is can measure Volume and Flow Spirometers have a time capacity. Accuracy: How well it can measure a known reference value. A volume or flow measuring device is perfectly accurate if it indicates values identical to reference values for volume or flow. The difference between the known reference value and measured reference value is called % error. The greater the accuracy, the smaller the error. Precision: Means reproducibility or validity. The reliability of measurements. When the measurements of reference values cluster together, the instrument is precise. An instrument can be precise but not accurate Linearity: Refers to the accuracy of the instrument over its entire range of capacity. Some devices may accurately measure large volumes or high flow rates but may not be accurate at low volumes or flows. If volumes and flows are accurate over the entire range, the instrument has linearity. Example of Question You are calibrating your PFT equipment and checking the volume via a 3.0 liter super syringe. The three volumes achieved are: 2.8 liters, 2.8 liters, 2.79 liters. Based upon the information obtained you would conclude which of the following? The machine is precise. The machine is accurate but not precise. The super syringe was advanced to slowly. The machine may have a leak. A. II and III ONLY B. I and IV ONLY C. II, III, and IV ONLY D. I, II, III, and IV SPIROMETRIC TECHNIQUE Patient Preparation Explain which medications to stop taking prior to test Describe the exact amount of time to withhold a bronchodilator is dictated by the onsetof action and the duration of the drug Salmeterol 12 hours Ipratropium 6 hours Terbutaline 4-8 hours Albuterol 4-6 hours Metaproterenol 4 hours Instruct if physician wants patient to stop smoking prior to test (24 hours) Important if patient to have a DLCO test performed Time of test Complete PFT 1 hours Spirometry 30 45 minutes Pulmonary history/physical assessment Height, weight, age, sex and race of the patient must be recorded. If the patient cant stand, use arm span width to approximate height. Determine any relative contraindications for PFT testing Hemoptysis of unknown origin Pneumothorax Unstable cardiovascular status (mi, pulmonary embolism, angina) Thoracic, abdominal or cerebral aneurysms Recent eye surgery (cataract ect) Acute disease process (vomiting, nausea) Recent surgery of thorax or abdomen Explaining the purpose of the test Keep explanations simple Explain, the test doesnt hurt but it will require your cooperation and lots of effort Positioning the patient Loosen any tight clothing If the patient is sitting, legs should be uncrossed and both feet on the floor Explaining and Demonstrating the Maneuver Explain procedure and what you expect from the patient If the patient needs oxygen, stop the O2 during the test maneuver and place back on the patient during rest periods Demonstrate the maneuver; explain that 7-8 FVC maneuvers may be needed Coach the patient throughout the maneuver Proper Performance and Careful Inspection of each maneuver Acceptability Criteria (5 criteria) Good start of the test (no hesitation) quick and forceful start An extrapolated volume of less and or = to 5% of FVC or 150 mL, whichever is greater No coughing (especially during the first second); If patient coughts with each manuever, indicate in comment section No variable flows; flows should be consistent No early termination; minimum exhalation of 6 seconds unless there is a plateau (no change in volume) for at least 1 second on V-T curve Test must be reproducible (valid). There must be consistency of effort. The 2 largest FVC from acceptable maneuvers should not vary by more than 0.2 L and the two largest FEV1 from acceptable maneuvers should not vary by more than 0.2 L A minimum of three acceptable efforts should be obtained. If a single acceptable test cannot be performed after 8 attempts, the testing can be discontinued. Patients can have spirometry induced bronchospasm where every tests shows deteriorating flowrates. All volumes and flow must be reported at BTPS Reference Values Predicted values are based on the patients Height Age Sex Race Common Reference Values Crapo Knudson Morris Cherniack Enright RULES FOR INTERPRETING PFT RESULTS A minimum of three acceptable procedures should be reported The tests must be valid or reproducible Use the two highest FVC and the two highest FEV1 to determine validity The two highest FVC values must be valid within 0.2 L of each other The two highest FEV1 values must be valid within 0.2 L of each other Report the highest FVC of the three trials Report the highest FEV1 of the three trials Determine the BEST TEST Add the FVC + FEV1 of each trial to determine the Best Test (Trial) Use the best test to report other volumes and flow measurements other than FVC and FEV1 (Example: FEF 25-75%, FEF 200-1200, Peak Flow, etc.) Determine the FEV1% Predicted Can use the highest FEV1 of the three VC maneuvers  EMBED Equation.3 = % Predicted Determine the %FEV1 (FEV1/FVC) (may also be written FEV1%) Use the highest FEV1 and the highest FVC (can use 2 different tests as long as both tests are valid. Example: use FEV1 from trial #1 and the FVC from trial #2  EMBED Equation.3  Determine if post bronchodilator study is needed If the FEV1 is less than 70%, a post bronchodilator study should be ordered. FEV1 should be used to determine the response to a bronchodilator. Peak flowrate should only be used if bedside spirometry (FEV1) cannot be done The % change in the FEV1 required for a substantial response is 12% (both a 12% improvement and an absolute improvement of 200 mL is required)  EMBED Equation.3 . Example: FVCFEV1FEF25-75%Trial #14.0 L3.0 L2.6 L/secTrial #23.8 L3.3 L2.4 L/secTrial #33.9 L3.1 L2.5 L/secThe FEV1 predicted is 3.8 LAre the tests valid? _______________What FVC should be reported? ___________________What FEV1 should be reported? ___________________What FEV1% predicted should be reported? _______________________What FEV1% should be reported? _______________________________What FEV25-75% should be reported? ______________________________Should a post bronchodilator test be ordered? _____________________ BEFORE AND AFTER BRONCHODILATOR STUDIES Before- and After-Bronchodilator Study is indicated when the FEV1% is less than normal. Usually an FEV1% less than 70% Withhold Medications MedicationTime to withholdb2 agonists8 hoursSustained b2 agonists12 hoursMethylxanthines12 hoursAtropine like drugs8 hoursCromolyn Sodium8-12 hoursInhaled steroidsmaintain dosage** times may be adjusted for individual patients Some patients may be unable to withhold bronchodilator therapy before the procedure. These patients should be instructed to take bronchodilators as needed and indicate this in the interpretation section. After the b2 agonist bronchodilator is administered, wait 15 minutes before administering the post bronchodilator test. If Atropine-like drugs are given, wait 30 60 minutes before administering the post-bronchodilator test. FEV1 is the most commonly used test for quantifying bronchodilator response. FEV1% should NOT BE USED to evaluate post bronchodilator results. The pitfall to using FEF25-75% is because the value is heavily dependent on the size of the FVC. It is common to see improvements in FEV1 after bronchodilator administration but no improvement (or a decrease) in the FEF25-75%. If FEF25-75% or flows such as FEF50% are used, they should be isovolume corrected for changes in FVC. This means that you use the before bronchodilator FVC to define the 25% and 75% points for the after-bronchodilator measurement.  EMBED Equation.3  If the FEV1 or FVC increase by 12% and 200 mL this is considered significant response. If FEF25-75% is used and is isovolume corrected, 20% -30% is considered significant response. MEASUREMENT OF LUNG VOLUMES AND GAS DISTRIBUTION TESTS Methods of Measuring Lung Volumes Three lung volumes cannot be directly measured RV FRC TLC Methods available to measure these volume/capacities are listed below MethodLung Volume MeasuredCommentsClosed Circuit: He DilutionFRC Underestimates FRC in COPDOpen Circuit: N2 washoutFRCUnderestimates FRC in COPDPlethysmographVTG (FRC)Most accurate May even overestimate lung volumesChest X-ray: P-A and lateral chest filmTLCNot accurate in presence of diffuse, space occupying disease X-rays taken at full inspiration Planimeter and ellipse method  Open Circuit (Nitrogen Washout) The Nitrogen concentration in the lungs is assumed to be 75-80%. After the patient breathes 100% oxygen for several minutes, the nitrogen in the lungs is gradually washed out. The test usually continues until the nitrogen concentration is 1% or less. In a normal person, this should take 3-4 minutes. In COPD, the time to wash out nitrogen exceeds 7 minutes. Monitor the nitrogen concentration throughout the test. If a leak occurs, nitrogen from room air enters the system and the nitrogen concentration abruptly rises (page.110) Washout times should be reported. Repeat the nitrogen washout procedure with a 15 minute interval between trials until you obtain two FRC values that agree by 10% (measured at BTPS).  EMBED Equation.3  Closed Circuit (Helium Dilution) A spirometer is filled with a known volume of air. Helium is added until the Helium concentration in the spirometer is 10%. The patient breaths through a valve that allows for rebreathing (a carbon dioxide absorber is placed in line). Oxygen is added to the spirometer system to maintain an FiO2 at or above 21%. CO2 absorber or scrubber is soda lime (when the color changes from white to blue you need to replace). A H2O absorber used is calcium sulfate (when color changes from blue to pink you need to change) Patient breathes until equilibration is complete (usually 3 minutes). The final concentration of He is recorded.  EMBED Equation.3   EMBED Equation.3  Multiple trials must be within 10%. No leaks can be present from mouth, nose or ears. (a ruptured tympanic membrane will cause a leak in the system. The Helium analyzer is a Wheatstone bridge and works on thermal conductivity. Thoracic Gas Volume (VTG) The VTG is the gas contained in the thorax whether in communication with the patients airways or trapped in any compartment of the thorax. It is measured at end expiratory level and represents the FRC. VTG is measured using the body plethysmograph (body box). The technique is based on Boyles Law. In the body box, the patient pants while the airway is occluded by an electrical shutter. The patient pants at a rate of 1-2 breaths/sec with an open glottis. Gas within the chest is alternately compressed and decompressed by the action of the ventilatory muscles. Acceptable Criteria for VTG The panting maneuver shows a closed loop without drift or other artifact The panting frequency is 1 Hz. Tangents or angles should agree within 10%. Derived lung volumes should be within 10%. Reported VTG is averaged from 3 to 5 acceptable panting maneuvers. It is often useful to compare FRC values obtained by plethysmography with values obtained from gas dilution methods, particularly in patients with obstructive disease. The ratio is usually near 1.0 in subjects with normal lungs (FRC box/FRC gas). As the ratio increases, more air trapping is present. Boyles Law V1P1 = V2P2 Boyles Law rearranged to solve for Thoracic Gas Volume (V2)  EMBED Equation.3  where, (V = change in body box volume when panting (P = change in alveolar pressure measured at the mouth P1 = atmospheric pressure (alveolar pressure at end expiration) FLOW VOLUME LOOPS Types Normal Obstructive Restrictive Fixed Airway Obstruction Variable Extrathoracic Variable Intrathoracic Parameters identified on a Flow Volume Loop Exhalation is usually on top Inhalation is usually on bottom Flow on vertical axis PEFR PIFR FEF25%, FEF50%, FEF75% FIF25%, FIF50%, FIF75% FEV1, FEV2, FEV3, FEV0.5 FEF50%/FIF50% Volume on horizontal axis FVC Criteria Three acceptable F-V loops should be obtained. Sharp rise to the PEFR. If not, suspect poor effort or large airway obstruction. F-V loops are indicated to detect upper airway obstructions (UAO) (mouth - trachea). Extrathoracic obstruction occurs above the suprasternal notch. Intrathoracic obstruction occurs below the suprasternal notch. UAO is confirmed by radiographs, CT scans and direct visualization (bronchoscopy). Comparison of expiratory and inspiratory flows at 50% of the FVC (FEF50%/FIF50%) helps determine the site of obstruction. In healthy subjects, the normal ratio is 1.0 or slightly less. (0.8 to 1.0) Variable Extrathoracic Normal expiratory flows but decreased inspiratory flows. The FEF50%/FIF50% is usually greater than 1.0. The obstruction is occurring outside the thorax so the expiratory portion of the curve appear normal and the inspiratory portion of the curve is squared off. Causes Seen with upper airway tumor Edema of epiglottis Vocal cord paralysis Vocal cord adhesions Foreign body in area above suprasternal notch Variable Intrathoracic Normal inspiratory flowrates but decreased expiratory flowrates The expiratory limb is squared off and the inspiratory limb appears normal. The FEF50%/FIF50% is usually less than 0.8. Causes Tracheomalacia Polychondritis Tumor near the carina/trachea Fixed Airway Obstruction Fixed Airway Obstruction produces a fixed F-V loop. This results in equally reduced flowrates at 50% of the inspiratory and expiratory phase. This results in a normal ratio. Causes Tracheal stenosis (watch for this after extubation) Goiter Large foreign body Tumor The loop is squared off (has a plateau) on both inspiration and expiration. RESPIRATORY MUSCLE STRENGTH Maximum inspiratory pressure (MIP) MIP is the lowest pressure developed during a forceful inspiration against an occluded airway. It is usually measured at maximal expiration (RV) and recorded as a negative number in either cm H2O or mm Hg. Sometimes it is measured at FRC. Subject is connected to a one way valve & pressure manometer via a mouthpiece (nose clips are needed). A small leak is introduced between the occlusion and the patients mouth. The leak eliminates pressures generated by the cheek muscles by allowing a small amount of gas to enter the oral cavity. This does not significantly change lung volume or the pressure measurement. Pressure Measurements Devices Manometer Aneroid type gauge Pressure transducer Linearity The device should be able to record pressures from 10 to 200 cm H2O Values Normal adults should generate inspiratory pressures greater than -60 cm H2O (-80 to -120) Values of 20 cm H2O or less indicate a need for mechanical ventilation MIP is a measure of inspiratory muscle strength & the patients ability to generate an effective cough. Decreased values are seen with Neuromuscular diseases Hyperinflation of the lungs (COPD) Chest wall or spinal deformities (kyphoscoliosis) Decreased inspiratory muscle strength MIP is also used to assess Response to respiratory muscle training Muscle strength during mechanical ventilation Validity Accurate measurements depend on subject effort. At least three maximal efforts should be recorded. The best efforts should be reproducible within 10% or 10 cm H2O, whichever is greater. Pressures tracing should show 1 to 3 seconds of sustained effort. The maximum value should be recorded. Maximum expiratory pressure (MEP) MEP is the highest pressure that can be developed during a forceful expiratory effort against an occluded airway. It is measured at maximal inspiration and reported as a positive number in either cm H2O or mm Hg. Subject is connected to a one way valve & pressure manometer via a mouthpiece (nose clips are needed). A small leak (1mm diameter leak) is introduced between the occlusion and the patients mouth. The leak eliminates pressures generated by the cheek muscles. This does not significantly change lung volume or the pressure measurement. Pressure Measurements Devices Manometer Aneroid type gauge Pressure transducer Linearity The device should be able to record pressures from 10 to 200 cm H2O Instructions Patient is instructed to inhale maximally. The airway is then occluded and the subject exhales maximally against the occluded airway for 1-3 seconds. Cardiac outputs can be reduced by the high thoracic pressures (Valsalva maneuver) Values The MEP is usually larger than the MIP in healthy subjects. Values depend on the function of the abdominal and accessory muscles of respiration, & the elastic recoil of the lungs and thorax. Healthy adults can generate MEP of over 100 cm H2O (men can generate pressures as high as 200 cm H2O. A MEP value of + 40 cm H2O is probably enough to cough effectively and move secretions. MEP is used to assess expiratory muscle strength and the ability of patients to cough effectively. Decreased values are seen with expiratory muscle weakness: Neuromuscular diseases High cervical spine fracture Damage to nerves controlling abdominal and accessory muscles (MIP may be normal in these patients) Obstructive lung diseases (because of high residual volume) Validity Accurate measurements depend on subject effort. At least three maximal efforts should be recorded. The best efforts should be reproducible within 10% or 10 cm H2O whichever is greater. Pressures tracing should show 1 to 3 seconds of sustained effort. The maximum value should be recorded. Body Plethysmography Can be used to measure TGV (FRC) Lung Compliance Airway Resistance and Specific Airway Resistance Conductance and Specific Conductance Airway Resistance (Raw) Definition  EMBED Equation.3  Raw is the difference between mouth pressure and alveolar pressure divided by flow. It is recorded in cm H2O/L/sec. Normal value is 0.6 to 2.4 cm H2O/L/sec at flowrates of +/- .5 L/sec The majority of Raw if found in the mouth, nose trachea, bronchi. Nose, mouth and upper airway 50%. Trachea and bronchi 30%. Small airways 20%. Raw is ( at increased lung volumes and (at decreased lung volumes. Higher lung volumes have lower Raw because the airways have a larger diameter. Lower lung volumes have higher Raw because the airways have a smaller diameter. This relationship is hyperbolic. Technique The patient breathes on a mouthpiece shutter system inside the airtight body box. Raw requires two maneuvers: Open shutter panting Closed shutter panting With the shutter open, the patient performs a gentle panting maneuver. A breathing rate of 2-3 breaths/sec is recommended. The patient performs 3 to 8 pants. The relationship between flow and pressure is plotted and produces an S-shaped curve. A line is constructed through the center between +/- 0.5 L/sec. The tangent of this line is determined and used in the calculation. After the open shutter panting, the shutter is closed and the patient performs an additional 3-8 pants. The relationship between mouth pressure changes and body box changes are recorded. A line is constructed through the series of straight lines and the tangent of the line is determined. The tangent is used to determine Raw. Panting frequency should be 1.5 3.0 Hz for the open and closed panting maneuver. Carbon Monoxide Diffusing Capacity Definition Diffusion is the flow or movement of gas molecules from an area of higher concentration to an area of lower concentration. In the PFT lab, diffusion refers to the transfer of gas between the alveoli and pulmonary capillary blood and is called diffusing capacity. Two Tests: Steady State Single breath (most commonly used) DLCOsb normal value is 25 mL/min/mm Hg Patients who show DLCO results within +/-20% of the predicted values are considered to be within normal limits (80 120% of predicted). Description Carbon Monoxide is used for the test because it has a greater affinity for Hb (210 times that of O2) It is soluble in blood. Concentration in venous blood is insignificant. The measurement of DLCO involves the rate of consumption (uptake) of CO by the blood. The rate of diffusion across the AC membrane depends on: The difference in gas tension (partial pressure) in the alveolus and the plasma The surface area available Tumors Destruction of A-C membrane (emphysema) Body size (larger body sizes will increase DLCO because of ( surface area) Age (DLCO decreases in patients over 20 years because of ( surface area) The distance the gas molecules must travel Tissue characteristics (pulmonary fibrosis or increased interstitial fluid). Uptake by RBC Hb level Pulmonary capillary blood volume High carbon monoxide levels (smokers) Pulmonary blood flow (CO, exercise, pulmonary embolism) Body position DLCO is 15-20% higher in supine position than standing position Age/body size DLCO decreases over age 20 Single Breath DLCO Patient is instructed to empty his/her lungs then inhale as deeply as possible a test gas mixture which contains known concentrations of CO, He, O2 and N2, then holds his breath for 10 seconds. Then the patient exhales and a sample of the exhaled gas is collected and analyzed. The DLCO and alveolar volume (VA) is calculated. The PFT equipment must have a CO analyzer and a He analyzer CO analyzer most commonly used is a infrared CO analyzer and works on the principle of infrared absorption. He analyzer works on the thermal conductivity principle. The test gas should contain 0.3% CO 10% He (methane is sometimes used as the tracer) 21% O2 (unless you are at high altitudes, then you use ( FIO2 to get a PIO2 of 150 torr) Balance N2 As the test gas is drawn into the lungs it is distributed into the alveoli (including the residual volume). CO will diffuse across the AC membrane but the exhaled CO will be less than the inspired CO concentration for two reasons: Diffusion into the blood and Dilution into the TLV. The inert gas He acts as a tracer and its dilution can be used to determine how much reduction in the CO concentration occurred because of dilution. Patient Preparation The test should be performed greater than 2 hours after eating. Oxygen should be discontinued greater than 5 minutes before the test or if unable to discontinue oxygen, then it needs to be indicated on report. Smoking should be stopped 24 hours before test and the time of the last cigarette recorded. No heavy exercise before the test. No alcohol for 4 hours before the test. Test performed with patient seated greater than 5 minutes before the test. Two acceptable trials are needed that agree within reproducibility criteria. Inspiration of test gas should be less than 4 seconds. Inspiratory volume should be from RV to TLC, Breath-hold must be 9 to 11 seconds. The expiration should be smooth and expiratory time less then 4 seconds. Allow 4 minutes between trials. Two acceptable trials must agree within +/-10% or 3 mL/min/mm Hg, whichever is larger. If doing a post bronchodilator DLCO, wait 30 minutes before doing post DLCO. Alveolar Volume: The tracer gas (He) is used to determine the alveolar volume Corrections/Adjustments The amount of Hb affects the DLCO. A Hb value should be obtained on each patient having a DLCO and a correction for Hb should be made. The greater the Hb level, the higher the DLCO value. The less the Hb level, the lower the DLCO value. Corrected DLCO = Measured DLCO /(0.06965) x (Hb) DLCO should be corrected for COHB DLCO should be corrected for altitude The DLCO should also be evaluated with regard to the lung volume (DL/VA) This helps to differentiate diffusion abnormalities caused by A-C membrane abnormalities from diffusion abnormalities caused by small lung volumes (fibrosis). Restrictive Lung Disease with small lung volumes will have a decreased DLCO, but a normal DL/VA ratio. This implies the A-C membrane is intact. Pulmonary Emphysema or Pulmonary Fibrosis will have a decreased DLCO and DL/VA. DL/VA is measured as ml/min/mm Hg/L. FactorsIncreased DLCO Decreased DLCO1. ExerciseX2. ( Cardiac Output (left to right cardiac shunts)X3. Supine PositionX4. CHF (early stages)X (due to increased blood volume)5. PolycythemiaX6. AnemiaX7. Carboxyhemoglobin (cigarette smoking)X8. FibrosisX9. Pulmonary emphysemaX10. Pulmonary embolismX11. Pneumonectomy or lobectomyX BRONCHOPROVOCATION TESTING Indications Asthmatics evaluated in a symptom free period may have a normal chest x-ray and normal Pulmonary function testing. Under these circumstances, provocative testing can be used to induce bronchospasm. It is also used to screen individuals who may be at risk from environmental or occupational exposure to toxins. Pulmonary function parameters are assessed before and after exposure to the challenge. FEV1 is the parameter most commonly used as well as airway resistance and conductance. Methods The most commonly used bronchoprovocative stimulus is methacholine. Other stimuli include histamine, exercise, eucapnic hyperventilation, and inhaled aerosolized hypotonic or hypertonic aerosolized saline. Methacholine (Provocholine) is a parasympathomimetic drug . Accepted criterion for hypersensitivity is the demonstration of a decrease in FEV1 by 20% or more below the baseline value after inhalation of methacholine (positive test). The methacholine concentration at which this 20% decrease occurs is called the provocative dose (PD20%) provocative concentration (PC20%). The dosages used will not elicit a response in a patient with normal airways. This dosage is usually 8 mg/mL or less. Positive test A 10% -20% decrease in FEV1 after inhaling diluent A 20% decrease in FEV1 after inhalation of the methacholine (or histamine) A decrease in FEV1 may not evoke a response in all individuals A 35% - 45% decrease in SGaw Patients tested should be asymptomatic (no coughing, no wheezing) Baseline FEV1 should be 80% or greater than their expected value. A physician should be immediately available. Medications for reversal (epinephrine) and a code cart should be available. Some labs also require a written consent form from the patient. Therapists should be BLS or ACLS certified. The room should be well ventilated and filters or exhaust systems may be desirable. RCP with asthma should not perform the tests. Techniques Used Two minute tidal breathing method The patient breaths quietly for 2 minutes. Five deep breath method Patient takes 5 deep breaths from FRC to TLC using a dosimeter or nebulizer. Inspiration should be 1 to 5 seconds with a breath-hold of 2-5 seconds. A dosimeter is a device used with a nebulizer which uses an electrical valve system. It uses a sensor to determine inspiratory effort. When an inspiratory effort is sensed, a valve is triggered and compressed air is admitted into the nebulizer for a selected period of time. (0.6 seconds) Not all nebulizers can be used with a dosimeter. Those that can must have a port to attach the sensor. Cost: $1500 to $2000.00 Dosimeters need to be powered at 20 psi. Patient begins be inhaling 5 breaths of nebulized diluent (normal saline). The breaths should be slow and deep from FRC to TLC with breath hold. After 3 minutes, spirometry is repeated. The highest FEV1 after inhalation of the diluent becomes the control. If the FEV1 is not reduced by more than 10%-20%from the baseline value, inhalation with Methacholine is started. Some patients with highly reactive airways may have a positive response to the diluent. Dosing Schedule Schedule #1 Schedule #2 Diluent Diluent 0.03 mg/mL 0.06 mg/mL 0.06 mg/mL 0.25 mg/mL 0.125 mg/mL 1 mg/mL 0.25 mg/mL 4 mg/mL 0.5 mg/mL 16 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 16 mg/mL 5 inhalations are done at each concentration. At 30 and 90 seconds spirometry is repeated. The time interval between doses should be 5 minutes The highest FEV1 is selected from the 3 trials. The test is stopped when FEV1 decreases by 20% or the maximum concentration is reached. A fast acting bronchodilator is given to reverse the bronchospasm.  EMBED Equation.3  X = control FEV1 (after diluent) Y = current FEV1 (after methacholine inhalation) Example: What is the % drop in FEV1 after 0.60 mg/mL in the test results below? What is the PD20% (PC20%) for the following test results? Methacholine dosage FEV1 Baseline FEV1 3.6 L 0.000 mg/mL (saline) 3.5 L 0.31 mg/mL 3.3 L 0.60 mg/mL 3.1 L 1.25 mg/mL 2.8 L 2.50 mg/mL 1.9 L Answer: What is the % drop in FEV1 after 0.60 mg/mL?  EMBED Equation.3  What is the PD20% (PC20%) for the following test results? 20% of 3.6 L = 0.72 3.6L 0.72 L = 2.88 L The concentration that resulted in a FEV1 of 2.88 L is 1.25 mg Answer: 1.25 mg Criteria for Acceptability The subject should withhold all bronchodilators before the test; patient should be free of upper or lower respiratory infection and not ingest any caffeinated beverages before the test. Spirometry and/or plethysmographic efforts must meet standard criteria for acceptability and reproducibility. Two FEV1 measurements should be within 200 mL. SGaw should be within 10% after each challenge. Nebulizer used should produce aerosol particles in the 1-4 um range. All clinical signs and symptoms should be documented (or absence of). RESTRICTIVE DISEASE STATES Idiopathic fibrosis Alveolar wall inflammation resulting in fibrosis. The patient often develops pulmonary hypertension and x-ray shows honeycombing. Can be caused by: Drugs Autoimmune disease Rheumatoid arthritis Systemic lupus Scleroderma Decreased DLCO Steroids is the treatment used and PFT tests should be done to monitor the disease Pneumoconiosis Inhalation of dust particles in the range of 0.5 5 m. Work or environmental history is very important; pulmonary fibrosis develops. Sarcoidosis Granulomatous disease that affects people between ages of 20 and 40 years old. Macrophages are seen in the tissue of the lungs and lymph nodes. The lymph nodes   E H = I # < ?R5ijPd678IJim5H*OJQJ^JaJ5OJQJ^JaJH*OJQJ^JaJCJOJQJ^JaJCJOJQJ^JaJOJQJ^JaJL+,@Ae 6 L e  J  # G & F h@ h8@@@  & F h8@@  h8@@@ & FG g w = J  # =  & F & F & F & F h8@@@ & F h@?S7Ap dow6hk & F & F & F & F & Fkosvy+AgBXgo & F & F & F & F & F)Pe #/`ky & F & F & F & F & F#-b #2Day} & F @ & F @ & F & F & F9Fse4CR5 & F h@ & F h8@@@ & F @ & F @ & F @ & F FJUW$47RX_eh 5 !=!"""#V%t%'"(**1,D,H,R,V,^,g,h,,,---...S.U.Y.\.].k.$///0001J1g111113333m4x4 j5OJQJ^JaJ5H*OJQJ^JaJ5OJQJ^JaJOJQJ^JaJH*OJQJ^JaJO57iPS 6 ?!!-""""#.# & F h & F h@ & F h@.#.$;$[$|$$$$%V%u%%y&&J'W''#(b(()>)c)) & F @ & F @ & F & F h & F h@ & F h@))v***++-+@+K+Z+h+}++++++,1,E,S,_,d,, & F @ & F @ & F @ & F & F @,,,---.l....../i////20l000J1111 & F @ & F & F @ & F @11I2o2222222333$3G3333 5{5555656 & F @ & F @ & F @ & F @ & F @x45556666666666677999:(;;;<<<=> >> ??#@(@+@[@\@e@3AD?DjDDE`EaEEEEEFFFFJ@OJQJ^JaJ5OJQJ^J OJQJ^J jOJQJ^JaJ jOJQJ^JaJjEHOJQJU^JaJjK CJUVjOJQJU^JaJ5OJQJ^JaJOJQJ^JaJ:56Z6i66667I7w7777#889:9`9999:M:[:|::: & F @ & F @ & F @ & F @:: ;);T;;;<K<<X== >W>>> ?\@3AZBnBcC{CCC?D & F @ & F @ & F @ & F @?DVDjDDE4EJEaEvEEE FF1FLFrFFF5GRG_GGGG & F @ & F @$ & Fa$$ & Fa$$ & Fa$$ & Fa$GH9H\HuHHHIOIyII$JkJJJJ K5KuKKKK & F @ & F @ & F @ & F @ & F @ & F @JJKKKL.LBLLLfMgMMMNOO+OkOmOOO P$P%P;Po?oWoooooooooooooooooooooooppp p pppppppp p%p(p,p/p3p6p7pQpRpUpVpWp_ph8qH*OJQJ^Jh^OJQJ^Jh8q5OJQJ^Jh^H*OJQJ^J OJQJ^Jh8qOJQJ^J jDh8qOJQJ^JGVoWoooooooop7pRpWpapppp6qvqqrrr & F T & F T & F T & F  T_p`pappppppppppp4q6qsqvqqqqrrNrQrUrXr_r`rrrrrrrrs s's*s.s1sMsOssssstt't)ttQtStttttt#u&u-u0u4u7uƦƦhOJQJ^Jh5OJQJ^JhH*OJQJ^Jh8q5OJQJ^Jh^5OJQJ^J OJQJ^Jh8qOJQJ^Jh^OJQJ^J5OJQJ^JAr sOssst(t=tRtttt&uRuYuhuwuuuu=v]vdvvv & F T & F T & F T7uPuRuXu[uguhuvuwuuuuuu;v=v[v]vcvdvevvvvvvvvvvvvww w!w"wCwDwwwwwxxxxx4x6xxxxxxxxxRySyyyyyyyyyyyyyzz:z;zhH*OJQJ^J5OJQJ^Jh5OJQJ^Jh8q5OJQJ^JhOJQJ^J OJQJ^Jh8qOJQJ^JJvvvw!wDwwx5xxyyyyyyzNzUzzz`{ & F & F & F & F & F & F T & F T;z`{{{{{|.|W|||||H}}}}F~~r%8 & F & F & F & F T & F T}}}}/~0~E~F~~~~~~~~ `eqr$&79KLUWӀ@Aց؁23Y[wЂh1eH*OJQJ^J5OJQJ^Jh1e5H*OJQJ^Jh8q5OJQJ^Jh+*H*OJQJ^Jh8qOJQJ^J OJQJ^JE8LVԀA؁[|΃NÄL˅ & F & F & F & FЂт҂قڂۂ /Iiz{|̓σ=>MN„Ä345JLɅʅ̅ȫȫȎyyyhmOJQJ^Jhm5OJQJ^Jh_XH*OJQJ^Jh1eOJQJ^J5OJQJ^Jh8q5OJQJ^Jh1e5OJQJ^J OJQJ^Jh8qOJQJ^J!h1e56H*OJQJ\]^J56OJQJ\]^Jh8q56OJQJ\]^J/˅-RjFÇևjۈ & Fp0^p`0 & F ` & F p0^p`0 & F  & F & F p0^p`0 & F 0^`0,-QRijtuv߆ !"EFWYćԇׇه݇އijوۈǷ jhmOJQJ^J jhmOJQJ^JhmH*OJQJ^JH*OJQJ^Jj hmEHOJQJU^JjK CJUVjOJQJU^Jhm5OJQJ^J5OJQJ^JhmOJQJ^J OJQJ^J6ۈDEUWkmˉ̉߉$%=>|}lm‹)*NPȌɌՌ,-QRݍ 1@ABTUĹhm5CJOJQJ^JhmH*OJQJ^JhmCJOJQJ^JhmCJOJQJ^J5OJQJ^Jhm5OJQJ^J OJQJ^JhmOJQJ^JDۈVl̉%}m‹*PʌՌ$ & Fa$ & F & F x^`x & F @ 0^@ `0 & F 0^`0 & F@ 0^@ `0 & F p0^p`0ՌRލAʎ֎;Sُb}@lȑё & FB^`B & F@ 0^@ `0 & F & F` & Fp0^p`0UWȎɎՎ֎89:<QT׏ُac|~ِؐې01?AjmǑȑБґշշ՞շՑ jhmOJQJ^J jhmOJQJ^JhmCJOJQJ^JhmCJOJQJ^JhmH*OJQJ^J OJQJ^JhmOJQJ^J5OJQJ^Jhm5OJQJ^Jhm5CJOJQJ^J9ёP^ǒے%aΔ#+]ǖ & F` & Fp0^p`0 & F T@@ & FB^`B & F0^`0 & F@ 0^@ `0NQ]^_`bǒՒ֒גْڒےmntubc̝yooCJH*OJQJ^J jOJQJ^JCJOJQJ^JCJOJQJ^JH*OJQJ^JhaFOJQJ^JhaF5CJOJQJ^JhaF5CJOJQJ^JhaF5OJQJ^Jhm5OJQJ^JhmCJOJQJ^JhmCJOJQJ^J OJQJ^JhmOJQJ^J+tƗЗ3O[٘ܘLNљԙ#&loΚ +,-.012ACú۰haFOJQJ^JCJOJQJ^JhmCJOJQJ^JhmCJOJQJ^Jhm5OJQJ^JhmOJQJ^J OJQJ^JH*OJQJ^JEǖߖtɗ[ۘNә%n2$Y & F^` & F@ 0^@ `0 & Fp0^p`0 & F`#%(46<NOQWZbfhnݜޜߜGHJKLMNy34㭢haF5OJQJ^Jhm5OJQJ^J5OJQJ^JhmH*OJQJ^JhaFCJOJQJ^JhmCJOJQJ^J OJQJ^JhmOJQJ^JhmCJOJQJ^J:ޜMS|̞ $ T@@$Ifa$l T@@ & F@ 0^@ `0 4578<=GHJKQTz{|ƞǞɞʞ˞̞͞Ξ +,01cd{|лȴЩлȴtȴȴȴ j5OJQJ^J5CJOJQJ^JhaFCJOJQJ^JhmOJQJ^J5H*OJQJ^JhaF5OJQJ^J OJQJ^Jhm5H*OJQJ^J5OJQJ^Jhm5OJQJ^J5CJOJQJ^JhaF5CJOJQJ^JhaF5CJOJQJ^J-(*+aG**$ T@@$Ifa$l T@@$Iflkd#$$IfTl    F6 ~ ` 0        44 lapT+,`bcaA$$$ T@@$Ifa$l T@h$If^h`lkd#$$IfTl    F6 ~ ` 0        44 lapTcdxz{aG**$ T@@$Ifa$l T@@$Iflkd#$$IfTl    F6 ~ ` 0        44 lapT{|aG**$ T@@$Ifa$l T@@$Iflkdo$$$IfTl    F6 ~ ` 0        44 lapTȟʟD* T@@$Iflkd$$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$lʟ˟̟ן؟D* T@@$IflkdO%$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$l˟̟ڟ۟ 56QRuvwMN֡ס-.12ҢZ[EFˤΤϤФҤԤhmH*OJQJ^Jhm5H*OJQJ^Jhm5OJQJ^Jh29H*OJQJ^Jh29OJQJ^Jh295OJQJ^JhmOJQJ^J OJQJ^J5OJQJ^J@؟ڟ۟D"! T@@q$If^q`lkd%$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$l D* T@@$Iflkd/&$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$l2D* T@@$Iflkd&$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$l2356ND* T@@$Iflkd'$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$lNOQRDkd'$$IfTl    F6 ~ ` 0        44 lapT$ T@@$Ifa$lRrsu$ T@@$Ifa$l! T@@>$If^`>luvס.a\SB55 & F0^`0 & F p0^p`0 & F  & Fkd'$$IfTl    F6 ~ ` 0        44 lapTѢ[FӤ#KYץ4vs!1S~ & F & F & F@ 0^@ `0 & Fp0^p`0 & F0^`0Ԥ"$:IJKXZst֥إ34Z\gitwrsͧΧ!01RS|*,.767PQѪӪGHSTh29H*OJQJ^Jhm5OJQJ^J OJQJ^JhmOJQJ^JV,QҪHvά Bryz @  & F @ @ x^@ `x & F & FB^`B & F@ 0^@ `0T uvͬάݬެ '(ABYZpqޭ ABQRpŸhr6<H*OJQJ^Jhr6<OJQJ^Jhr6<56OJQJ\]^Jhm56OJQJ\]^Jhm5OJQJ\^J5OJQJ\^Jh29H*OJQJ^Jh29OJQJ^Jhm5OJQJ^J OJQJ^JhmOJQJ^J3pr #$%&'67GHWXxzɯʯدۯ߯!"#/09:VWklϿ5OJQJ^Jhm5OJQJ^J5H*OJQJ\^Jhr6<5H*OJQJ\^Jhm5OJQJ\^Jj_(hr6<EHOJQJU^JjhKG CJUVjOJQJU^Jhr6<H*OJQJ^JhmOJQJ^J OJQJ^J4Ͱΰ45Jcαϱ/0%(VXϿ}CJOJQJ^JaJ5;OJQJ\^JaJOJQJ^JaJ5OJQJ^JaJ5OJQJ\^Jhm5OJQJ\^Jj*hr6<EHOJQJU^JjLG CJUVjOJQJU^Jhr6<H*OJQJ^J OJQJ^JhmOJQJ^J/zϱ(XIƴ۴ & F & F & F  & F  T@@ & Fp0^p`0 & F  & F T@@YgGLވ>*OJQJ^JaJ;OJQJ\^JaJUOJQJ^JaJ5;OJQJ\^JaJOJQJ^JaJCJOJQJ^JaJXYh^ #:GMˆވ T@@@ & F & F  @ & F  are large. Biopsy of the tissue Steroids are indicated PFT testing Lupus A chronic inflammatory disease of connective tissue that causes injury to the skin, joints, kidneys, CNS, and lungs. Often affects young women. AMYOTROPHIC LATERAL SCLEROSIS (ALS, Lou Gehrigs Disease) A muscle weakness and atrophy due to degeneration of motor neurons of the spinal cord, medulla and cortex. Etiology unknown (Can progress for 20-30 years) /0&P/ =!"#$% `Dd lb  c $A? ?3"`?2:M-= >DlJD`!~:M-= >DlJ @PLxuQ=K@$ hqEKBS(rFHHwZike+vr '(q#{2p  ¢tAȘF 뺖Z7j4A-S="D9n QqW&DLE-KB'|~[1(F֋kw\܏pcKd ^]%罼Nb؃dqgqڲ/P ~4T-]o&iᵠs;U0%}!=oQjIշs}ܮ|Wة"%M,p@s "~YDd c b % c $A? ?3"`?2ruСK1`!ruСK1H@xڍRKA~3.X( VXh'!0:utCA)ֱ:աuХD"`mo~V8 {o@@"QQB$"u]Ș<ӻu.@e`b#IGA1 u = A?<&Bt.fK uzNSh~גaFPYκSZo}ʽ7𞐼a1~qwK΅2vp3zLF]1t|3c\h;3yd?TdM{4 ]~"Ŝc%&I ʓ@/&5:VD/&=L(I*U& Ș#N`[LopDd hlb 3 c $A? ?3"`?2~3qWS}H*S`!~3qWS}H*@ \xcdd``b 2 ĜL0##0KQ* WفKRcgbR vx\ zjx|K2B* Rj8 :@u!f0109Y@qf;35VĠXdZQc@`|O`qVBS1oy<\ոcL`s +!Kz>01b{>wCaɬdps Kt23Eœ"E~ 05XB  I9`_& \982 v 0#(#RpeqIj. @ ]` "O4{Dd b I c $A? ?3"`?2> d~`!> d~0 ,dxcdd``$d@9`,&FF(`TI偌 A?d@o1@0&dT20<`b e-b YU wfjQ9A(316Qc@`6kE`AZU+a| =L?b皆|&?ᄚ{X*T,.A 27)?\1 C #A 1}0xt2DDR "EׄQ1p@EL@ _LnF  `E0s9fpAd9g$楧rA8$,ؑbI)$5" @ ]` "z3($$If!vh55w55@#v#vw#v#v@:Vl t655w55@T$$If!vh55w55@#v#vw#v#v@:Vl t655w55@T$$If!vh55w55@#v#vw#v#v@:Vl t655w55@T$$If!vh55w55@#v#vw#v#v@:Vl t655w55@TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TK$$If!vh5#v:Vl t65TX$$If!vh5 5/ #v #v/ :V l5 5/ TX$$If!vh5 5/ #v #v/ :V l5 5/ TX$$If!vh5 5/ #v #v/ :V l5 5/ TX$$If!vh5 5  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~~Root EntryA FQL8Data d.WordDocument@1ObjectPoolC'YmQL8QL8_1258455794;FYmQL8YmQL8Ole CompObjfObjInfo "#&)*+.12369:;>ADGJMNQTUVWXY[\]^_`acdefgi FMicrosoft Equation 3.0 DS Equation Equation.39q~2 Flow = Pressure  ResistanceEquation Native _12584574286 FYmQL8YmQL8Ole CompObj f FMicrosoft Equation 3.0 DS Equation Equation.39q¦1| Greatest FEV 1 Predicted FEV 1 100%ObjInfo Equation Native  _1258457633FYmQL8YmQL8Ole CompObjfObjInfoEquation Native v_12584603521FYmQL8YmQL8 FMicrosoft Equation 3.0 DS Equation Equation.39qZ$ FEV 1 FVC=FEV 1 % FMicrosoft Equation 3.0 DS Equation Equation.39qOle CompObjfObjInfoEquation Native ¶3| %Change=Post Drug - Pre DrugPre Drug100% FMicrosoft Equation 3.0 DS Equation Equation.39q_1191327037FYmQL8YmQL8Ole CompObjfObjInfo ž(' %change=Postdrug"PredrugPredrug100 FMicrosoft Equation 3.0 DS Equation Equation.39qEquation Native !_1191327978"FYmQL8YmQL8Ole $CompObj %fObjInfo!'Equation Native (_1191328000$FYmQL8YmQL8Ole ,p FRC=%N 2  Final ExpiredVolume%N 2  atmosphere FMicrosoft Equation 3.0 DS Equation Equation.39qCompObj#%-fObjInfo&/Equation Native 0_1191328029 )FYmQL8YmQL8xh FRC=%He Initial "%He Final %He Final SystemVolume FMicrosoft Equation 3.0 DS Equation Equation.39qOle 4CompObj(*5fObjInfo+7Equation Native 8³z SystemVolume=He Added (L)F He  Initial FMicrosoft Equation 3.0 DS Equation Equation.39q_1191328333.FYmQL8YmQL8Ole <CompObj-/=fObjInfo0?Equation Native @f_12584614453FYmQL8YmQL8Ole BCompObj24CfJ"D V 2 =VP 1 P FMicrosoft Equation 3.0 DS Equation Equation.39qVP9\~ Raw=PressureFlowObjInfo5EEquation Native Fr_1191332712,8FYmQL8YmQL8Ole H FMicrosoft Equation 3.0 DS Equation Equation.39qŠ(| % decrease =X-Y  x  100X   =  CompObj79IfObjInfo:KEquation Native L_1191333041=FYmQL8YmQL8Ole OCompObj<>PfObjInfo?REquation Native S FMicrosoft Equation 3.0 DS Equation Equation.39qqj % decrease =X-Y  x  100X   =  % decrease =3.5-3.1  x  1003.5   =.114100%=11.4% dropOh+'0  $0 P \ h t,MODULE D PULMONARY FUNCTION MEASUREMENTSGary M. MiglioNormalRick Zahodnic2Microsoft Office Word1TableJSummaryInformation(BZDocumentSummaryInformation8bHCompObjhq/ #v #v/ :V l5 5/ TX$$If!vh5 5/ #v #v/ :V l5 5/ TX$$If!vh5 5/ #v #v/ :V l5 5/ TX$$If!vh5 5/ #v #v/ :V l5 5/ TDd b J c $A? ?3"`?2?ω`!?ω F)dxcdd``d 2 ĜL0##0KQ* Wä@JRcgbR vqmfĒʂT @_L ĺE29@,a G L *ĠXdZQXAk9GLF`h`j61W&\$ՌD&k?M怚|K d5ɫ>aj|>6YJ)EPBF[!7T䒀0Uٌl@VrFb^:Aq0DZNJP4B]B :)l-- HĤ\Y\C D|b@%f~Gw$$If!vh55U5#v#vU#v:Vl t655U5Tw$$If!vh55U5#v#vU#v:Vl t655U5Tw$$If!vh55U5#v#vU#v:Vl t655U5Tw$$If!vh55U5#v#vU#v:Vl t655U5Tw$$If!vh55U5#v#vU#v:Vl t655U5TDd `b K c $A? ?3"`?2DoI>憩`!DoI>憩^#(+xڕRM/awvM4[AYD!i}ŊFW*Ug'ȅKo3\T"!"<3yyff_v2 f*YXס&4A8_:sFq,Xt+G< JSLE:G B'}Wtl"PGpf 7Kر͛ ׵y*&#g97,[sM"Ϟ#k!MդW׈m~B1=yFES-2+l'=Rc~?)x뫹lTBKe+Rsn>{!{Dգ[)qmEduG wQ.. ^b">a8$o|xbۿSaUh(*^h@Q8Nh>9&oSDd b L c $A? ?3"`?2*u"ר<E`!*u"ר<6@@(.xڍRKA~3]#[ ĬH"!] ]9nyֵKxҏ!]*ޛ %7Unܸ8c 18@q6bF7/DD4 p(j"_֨eJF?υ+dQ"Bt;B:?I[f8)tq&∩?'LxjqE)s!{21kAIφtDaorG2T{vXP/_HW}%@jcْJ /+…&*EW RYeb%}^DvDsz:'#ӕn!'z/w}3ŵ9 ;o4K/sO_;psݹ^qKW(*U7EyРp& hn&ϓTDd b M c $A? ?3"`?2oFMܲ: `!oFMܲ: `PxڍR=OAC0詉 zi&Za,pF"Q j?ĂNJMh0FΙ̼݃7s+  |F(G(+Ѣyf}3 ͏F`\N(&E1`#W۬WnUJPcxc0]YmWe6a!W$lX~5u٭=S[mmB:H=Z;(TN:H/mZut])0iSr9PZgwX+^I7 E, `Q)m_]k3B_ N_3O8Пh^)ZCCbI߆.ߏJ+ ~o "Ϊ}*f\5LjDd `lb N c $A? ?3"`?2ArޅXU`!ArޅXUvX Vx}Q=KA};{3q"bq "6 UAFA"I?jeoa_a v`9{ .03͍@+?z)  #AQi$.KiѼ=D.Gh{,vjӽ5,EafOD*4ɨk+tc*A-s`s*^{7l㎙)Vɹj U+ɫ4Gz]Y9=:ݭ0?W>0dz(jrRNߺ8}EՌtB[AUotUp0iJ_Dd lb m c $A!? ?3"`? 2s3I9!`!}s3I9  &KxuQJA};˝9N h V6 b,-BB.r\#* b?%(x^ fy;fVX%!Q " (sjy.ZFJsȅ #FO# iT9IBNcI3r˂=. a܈OsY]p8N8QT21V+aKf7H:Qő$Y" ;6 䯓[Cloh*KZ(X^ bgޫjFۇ]lh%è+p :lhUrn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5Tn$$If!vh5 5` 5#v #v` #v:Vl5 5` 5TDd \ lb \ c $A? ?3"`? 2m6tx$(`!m6tx$`"!x}R=KA݋zw:. XEL M,,uE$a26JBsgwH"{f, h)5"E}D шP$Z$:"kR@sqA;Y Bq>"LJ+$vI B(=ʼwQ`Ƕ=M,6c~G$W.\Yg\CrUJYf#ݘ<CZG"xpFc#d &OnϪʩ/Y>%cەaK*]sϭ ,7Շ>,*]~|?DVW6tخ7x:Xb.{. !?wgDd b [ c $A? ?3"`? 2m04)A+`!m04) (`4>e SxڍT=hA~3ݭwk8?$*[rfD(V`Ŭ`ȱ;lDB+"X+ -FTj19o=,fޛy ?p@E QPX+hֹlvʭ L+nmV5.\l%KN؜I>c|4S~/ULUr9w_k[onr9_~';`Ʀ{=rzSȬ[13SX; ] 6^rfLa2|%sLzQmż𨈡ggp"uF &BEFW#ẆZ[ Z8Z^`xZ6t& ?5>̀<(u崺qiuPΟZ.* mL礔{)KhVYBl=@[꯭s0*:++08m*/?8Z= 2Ojd']@Dk_%dd_^_-q#G/Or@A>u ǖ$Z8 ~TaT%`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'<@< NormalCJ_HmH sH tH >@> Heading 1$$@&a$58@8 Heading 2$@&5\@\ Heading 3,$ h8@@@8@&^8`5DA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k@(No List :@:  Footnote TextCJ>@>  Comment Text$a$CJh$@h Envelope Address!@ &+D/^@ CJOJQJJ%@"J Envelope Return6CJOJQJD>@2D Title$ h8@@@a$5j`Cj  Table Grid7:V0@S Table Grid 5:V0    jjj# j 5\5\J@cJ Table Grid 7:V0    jjj#j# j 25\5\5\5\5\V !z!z!z!z!z!z!z!z! z! z! z! z! z!z!z!z!z!z!z!z!z!z!z!z!z!z zy y% -4?<CF1M5Ug[chowVlwV 4 :,r /  X !  NWj+,@Ae6LeJ#Ggw=J#=?S7Ap dow 6 h k o s v y   + A g    B X g o ) P e   # / ` k y #-b #2Day}9Fse4CR57iPS6?-..;[|VuyJW# b !>!c!!!v"""##-#@#K#Z#h#}######$1$E$S$_$d$$$$%%&l&&&&&&'i''''2(l(((J)))))I*o*******+++$+G++++ -{----.5.Z.i..../I/w////#001:1`11112M2[2|2222 3)3T3334K44X55 6W666 7\839Z:n:c;{;;;?<V<j<<=4=J=a=v=== >>1>L>r>>>5?R?_????@9@\@u@@@AOAyAA$BkBBBB C5CuCCCC.DDDEEDFFFFFGG#G'G,GEGKGSGZGdGlGmGGGGG!c!!!v"""##-#@#K#Z#h#}######$1$E$S$_$d$$$$%%%&l&&&&&&'i''''2(l(((J)))))I*o*******+++$+G++++ -{----.5.Z.i..../I/w////#001:1`11112M2[2|2222 3)3T3334K44X55 6W666 7\839Z:n:c;{;;;?<V<j<<=4=J=a=v=== >>1>L>r>>>5?R?_????@9@\@u@@@AOAyAA$BkBBBB C5CuCCCC.DDDEEDFFFFFFGG#G'G,GEGKGSGZGdGlGmGGGGG 0 > 0V< 0L> 0L> 0?<> 0>> 0>> 0>> 0>> 0>> 0>> 0>> 0?<> 09@> 09@> 0?<> 0@> 0@> 0?<> 0OA> 0OA> 0OA> 0OA> 0?<> 0B> 0B> 0B> 0B> 05C> 0B> 0C> 0B> 0B> 0B> 0D> 0D> 0D> 0D> 0D>0>0> 0?<> 0F> 0F> 0F> 0F> 0F> 0F> 0,G> 0,G> 0,G> 0,G> 0,G>0> 00 0mG 0mG 0mG 0mG 0mG 0mGH 0mGH 0mGH 0IH 0IH 0mGH 0 JH 0 JH 0 mGH 0JH 0JH 0JH 0 mGH 0uKH 0uKH 0uKH 0uKH 0uKH 0uKH0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0 00bO 0bObO 0ObO 0bObO0bO0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO0bO 0bObO 0bObO 0bObO 0bObO 0bObO 0bObO 0bObO 0 bObO 0 bObO 0 bObO 0bO 0U 0$V$V 0FV$V 0FV$V 0FV$V 0$V$V0$V0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V 0$V0$V 0$V 0$V 0$V 0$V0$V0$V0$V 0$V 0$V 0U$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0Z$V 0U$V 0f[$V 0f[$V 0f[$V 0\$V 0\$V 0f[$V 0f[$V 0f[$V 0f[$V 0f[$V 0U$V 0_$V 0_$V 0_$V 0_$V 0``$V 0``$V 0_$V 0la$V 0la$V 0la$V 0la$V 0la$V 0la$V 0_$V 0c$V 0c$V0$V 0$V0$V 0d$V 0d$V 0d$V 0d$V 0d$V 0d$V 0d$V0$V 0d$V 0We$V 0We$V 0We$V 0e$V 0e$V 0e$V 0e$V 0e$V 0We$V 07f$V 0d$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0h$V 0h$V 0h$V 0h$V 0i$V 0i$V 0i$V 0i$V 0i$V 0 Wf$V 0j$V 0j$V 0j$V 0j$V 0Rk$V 0Rk$V 0Rk$V 0 Wf$V 0k$V 0k$V 0k$V 0k$V 0]l$V 0]l$V 0]l$V 0]l$V 0k$V 0$V 0m$V 0!m$V 0!m$V 0!m$V 0!m$V 0!m$V 0!m$V 0o$V 0o$V 0o$V 0o$V 0o$V 0o$V 0!m$V 0Np$V 0Np$V 0Np$V 0!m$V 0`q$V 0`q$V 0`q$V 0`q$V 0!m$V 0r$V 0r$V 0 !m$V 0r$V 0r$V 0r$V 0r$V 0r$V 0m$V 0s$V 0s$V 0s$V 0s$V 0s$V 0s$V 0u$V 0u$V 0u$V 0u$V 0s$V 0Lv$V 0s$V 0v$V 0v$V 0v$V 0s$V 0w$V 0w$V 0w$V 0w$V 0w$V 0 s$V 0|y$V 0|y$V 0|y$V 0|y$V 0 s$V 0z$V 0z$V 0z$V 0z$V 0z$V 0$V 0{$V 0{$V 0{$V 0{$V 0{$V 0{$V 0R|$V 0R|$V 0R|$V 0R|$V 0R|$V 0F}$V 0F}$V 0F}$V 0R|$V 0R|$V 0R|$V 0R|$V 0 R|$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0 ~$V 0 ~$V 0 ~$V 0$V 0 0ʂʂ 0ʂʂ 0ʂʂ 0ރʂ 0ރʂ 0ʂʂ 0ʂʂ 0ʂ 0ʄʂ 0ʄʂ 0ʄʂ 0ʄʂ 0ʄʂ 0مʂ 0مʂ 0bʂ 0bʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0 مʂ 0 مʂ 0 مʂ 0Pʂ 0 مʂ 0ʂ 0ʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0ʂ 0ʂ 0ʂ 0ʂ 0Ljʂ 0ʂ 0ʂ 0Ljʂ 0Ljʂ 0tʂ 0tʂ 0tʂ 0tʂ 0tʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0 ʂ 0 ʂ0ʂ0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ  0ʂ 0vʂ 0ʂ 0vʂ 0vʂ 0vʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0vʂ 0Kʂ 0Kʂ 0Kʂ 0Kʂ 0vʂ 0vʂ 0vʂ 0vʂ 0 vʂ 0 vʂ 0 vʂ 0 vʂ 0!ʂ 01ʂ 0!ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0ʂ 0~ʂ 0~ʂ 0~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ0ʂ 0̔ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ0ʂ 0ʂ 0Yʂ 0Yʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0{ʂ 0{ʂ000+,@Ae6LeJ#Ggw=J#=?S7Ap dow 6 h k o s v y   + A g    B X g o ) P e   # / ` k y #-b #2Day}9Fse4CR57iPS6?-..;[|VuyJW# b !>!c!!!v"""##-#@#K#Z#h#}######$1$E$S$_$d$$$$%%%&l&&&&&&'i''''2(l(((J)))))I*o*******+++$+G++++ -{----.5.Z.i..../I/w////#001:1`11112M2[2|2222 3)3T3334K44X55 6W666 7\839Z:n:c;{;;;?<V<j<<=4=J=a=v=== >>1>L>r>>>5?R?_????@9@\@u@@@AOAyAA$BkBBBB C5CuCCCC.DDDEEDFFFFFFGG#G'G,GEGKGSGZGdGlGmGGGGG 0 > 0V< 0L> 0L> 0?<> 0>> 0>> 0>> 0>> 0>> 0>> 0>> 0?<> 09@> 09@> 0?<> 0@> 0@> 0?<> 0OA> 0OA> 0OA> 0OA> 0?<> 0B> 0B> 0B> 0B> 05C> 0B> 0C> 0B> 0B> 0B> 0D> 0D> 0D> 0D> 0D>0>0> 0?<> 0F> 0F> 0F> 0F> 0F> 0F> 0,G> 0,G> 0,G> 0,G> 0,G>0> 00 0mG 0mG 0mG 0mG 0mG 0mGH 0mGH 0mGH 0IH 0IH 0mGH 0 JH 0 JH 0 mGH 0JH 0JH 0JH 0 mGH 0uKH 0uKH 0uKH 0uKH 0uKH 0uKH0H 0H 0H 0H 0@@j@>8L8@>8L8Q՜.+,0 hp  Compaq<Y +MODULE D PULMONARY FUNCTION MEASUREMENTS TitleH 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0H 0 00bO 0bObO 0ObO 0bObO0bO0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO 0bO0bO 0bObO 0bObO 0bObO 0bObO 0bObO 0bObO 0bObO 0 bObO 0 bObO 0 bObO 0bO 0U 0$V$V 0FV$V 0FV$V 0FV$V 0$V$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V0$V 0U$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0[X$V 0Z$V 0U$V 0f[$V 0f[$V 0f[$V 0\$V 0\$V 0f[$V 0f[$V 0f[$V 0f[$V 0f[$V 0U$V 0_$V 0_$V 0_$V 0_$V 0``$V 0``$V 0_$V 0la$V 0la$V 0la$V 0la$V 0la$V 0la$V 0_$V 0c$V 0c$V0$V 0$V0$V 0d$V 0d$V 0d$V 0d$V 0d$V 0d$V 0d$V0$V 0d$V 0We$V 0We$V 0We$V 0e$V 0e$V 0e$V 0e$V 0e$V 0We$V 07f$V 0d$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0Wf$V 0h$V 0h$V 0h$V 0h$V 0i$V 0i$V 0i$V 0i$V 0i$V 0 Wf$V 0j$V 0j$V 0j$V 0j$V 0Rk$V 0Rk$V 0Rk$V 0 Wf$V 0k$V 0k$V 0k$V 0k$V 0]l$V 0]l$V 0]l$V 0]l$V 0k$V 0$V 0m$V 0!m$V 0!m$V 0!m$V 0!m$V 0!m$V 0!m$V 0o$V 0o$V 0o$V 0o$V 0o$V 0o$V 0!m$V 0Np$V 0Np$V 0Np$V 0!m$V 0`q$V 0`q$V 0`q$V 0`q$V 0!m$V 0r$V 0r$V 0 !m$V 0r$V 0r$V 0r$V 0r$V 0r$V 0m$V 0s$V 0s$V 0s$V 0s$V 0s$V 0s$V 0u$V 0u$V 0u$V 0u$V 0s$V 0Lv$V 0s$V 0v$V 0v$V 0v$V 0s$V 0w$V 0w$V 0w$V 0w$V 0w$V 0 s$V 0|y$V 0|y$V 0|y$V 0|y$V 0 s$V 0z$V 0z$V 0z$V 0z$V 0z$V 0$V 0{$V 0{$V 0{$V 0{$V 0{$V 0{$V 0R|$V 0R|$V 0R|$V 0R|$V 0R|$V 0F}$V 0F}$V 0F}$V 0R|$V 0R|$V 0R|$V 0R|$V 0 R|$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0~$V 0 ~$V 0 ~$V 0 ~$V 0$V 0 0ʂʂ 0ʂʂ 0ʂʂ 0ރʂ 0ރʂ 0ʂʂ 0ʂʂ 0ʂ 0ʄʂ 0ʄʂ 0ʄʂ 0ʄʂ 0ʄʂ 0مʂ 0مʂ 0bʂ 0bʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0مʂ 0 مʂ 0 مʂ 0 مʂ 0Pʂ 0 مʂ 0ʂ 0ʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0ʂ 0ʂ 0ʂ 0ʂ 0Ljʂ 0ʂ 0ʂ 0Ljʂ 0Ljʂ 0tʂ 0tʂ 0tʂ 0tʂ 0tʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0 Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0Ljʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0 ʂ 0 ʂ0ʂ0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ  0ʂ 0vʂ 0ʂ 0vʂ 0vʂ 0vʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0vʂ 0Kʂ 0Kʂ 0Kʂ 0Kʂ 0vʂ 0vʂ 0vʂ 0vʂ 0 vʂ 0 vʂ 0 vʂ 0 vʂ 0!ʂ 01ʂ 0!ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0ʂ 0~ʂ 0~ʂ 0~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0 ~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ 0~ʂ0ʂ 0̔ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ 0ʂ0ʂ 0ʂ0ʂ000000x4JrRaW^vaOeg5j.n_p7u;z}ЂۈU4ԤTp\ekpsG k5.#),156:?DGKmOTNUXUoUUUUU#VVVVVW`W4XXDYY$``)acaaYbdkVorv`{8˅ۈՌёǖ+c{ʟ؟2NRuz]_`abcdfghijlmnoqrtuvwxyz{|}~^-..]JqJsJ]KqKsKM)M+MU1U3UN[b[d[^^^^.^0^d#d%du|||#%V::::::::::::8@0(  B S  ?h^<i<j8:^TM4_ ddXcddX9*urn:schemas-microsoft-com:office:smarttagsplace8*urn:schemas-microsoft-com:office:smarttagsCity ). PX ---i.p...0!011<<??CCCCZGcGdGkGsT|TUU:XDX iu.2(,XW[+$0$J0N0??IIPP\\^^EhKhii/q7qV}Y}ΊЊϫ۫X::::::::::::::::::::Aee=J=?S7Ap d6 h y  A P / ` -b}4R57i6..VyJW""##1$$$$%%P&&i''(()J)))*$+++{--Z.i...//12M2222 3)334+8\8939Z:n:c;{;?<j<== >r>5?_?\@u@@AkBBB CuCCFFG,GEGKGmGGI5I J*J]JJM1M;MCMDMNMOM]M^McMdMMMMMMBNWNNNNNJOaObOOP5P6PP$VFVuVVV*WW X:XZX[XzXg[[_0_laaccdWeeeef7fafhhiRjjjRkk]ldlllmDmooopNpUp`qqqr.rrssuVvvvwwyyzz{{-|j|}}~~8ՂރʄքblP^ۈ+ߌtn,`KY4!S~AQҠϧ(IYh׬_z{XXB#DYVN 1@-eX>l4$~l"aNo\o4$>u ^ `56789;<CJH*OJQJS*TXaJo(hH.` P^` `POJQJ^Jo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`0B*OJQJo(phhH. 0^`056OJQJo(hH. (p0p^p`056B*CJOJQJo(phhH. @ 0@ ^@ `0o(hH.0^`0OJQJo(hH. 0^`0o(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.F ^ `56789;<CJH*CJOJQJS*TX^JaJo(hH.B ^ `56789;<CJH*CJOJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.808^8`0o(.^`o(.$ $ ^$ `o(.@ @ ^@ `o(.^`OJPJQJ^Jo(- L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.F ^ `56789;<CJH*CJOJQJS*TX^JaJo(hH.B ^ `56789;<CJH*CJOJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`0B*OJQJo(phhH. 0^`056OJQJo(hH. (p0p^p`056B*CJOJQJo(phhH. @ 0@ ^@ `0o(hH.0^`0OJQJo(hH. 0^`0o(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.^`o(. 0 ^ `0o(.  ^ `o(. ^`hH. ^`hH. L^`LhH. ^`hH. PP^P`hH.  L ^ `LhH.0^`0B*OJQJo(phhH. 0^`056OJQJo(hH. (p0p^p`056B*CJOJQJo(phhH. @ 0@ ^@ `0o(hH.0^`0OJQJo(hH. 0^`0o(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.h^`OJQJo(hHh^`OJQJ^Jo(hHohUU^U`OJQJo(hHh% % ^% `OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhee^e`OJQJ^Jo(hHoh55^5`OJQJo(hH0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.F ^ `56789;<CJH*CJOJQJS*TX^JaJo(hH.B ^ `56789;<CJH*CJOJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`0o(.p0p^p`0o(.  ^ `o(.  ^ `OJPJQJ^Jo(-xx^x`o(. HLH^H`LhH. ^`hH. ^`hH. L^`LhH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.F^`56789;<CJH*CJOJQJS*TX^JaJo(hH.B ^ `56789;<CJH*CJOJQJS*TXaJo(hH.` P^` `POJQJ^Jo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.` P^` `POJQJ^Jo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.` P^` `POJQJ^Jo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`0B*OJQJo(phhH. 0^`056OJQJo(hH. (p0p^p`056B*CJOJQJo(phhH.@ 0@ ^@ `056o(hH.0^`0OJQJo(hH. 0^`0o(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.` P^` `POJQJ^Jo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`056OJQJ^Jo(hH.'xX^x`X56CJOJQJ^JaJo(hH.B ^ `56789;<CJH*OJQJS*TX^JaJo(hH.> ^ `56789;<CJH*OJQJS*TXaJo(hH.'` P^` `P56CJOJQJ^JaJo(hH. x^`xo(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.0^`0B*OJQJo(phhH. 0^`056OJQJo(hH. (p0p^p`056B*CJOJQJo(phhH.@ 0@ ^@ `056o(hH.0^`0OJQJo(hH. 0^`0o(hH() P^P`o(hH. ^`o(hH.  ^ `o(hH.[%m^2}| -bHNo\o1@-e!&c X>l  5Ybo &. P..N 6bD;3o{ %MU kRZe$5b>uB#3'3rU0G7c`F~l@c z,3       uxF$[8TKz     HplH˰6U(Z4             <>^^[               ʚr$*y%fa    0M:M;M?MDMNMOMXM^MdMnMoMxM~MMMMMMMMMMMMM#N$NVNWNNNNNOO`OaOPPP%P6P7PCPKPLPbPkPlP|PPPPPPPPPPPPVVVVV WW)W*WDWHWcWdWsW~WWWWWYXZXi| (*+,`bcdxz{|ȕʕ˕̕וؕڕە 2356NOQRrsuvUX9o@BB$$  BBLPQRV@XZ@@UnknownGz Times New Roman5Symbol3& z Arial?Wingdings 3?5 z Courier New;Wingdings"qh 4 4sQY<QY<t$>4d  3QHX)?2*MODULE D  PULMONARY FUNCTION MEASUREMENTSGary M. Miglio Rick Zahodnic                          FMicrosoft Office Word Document MSWordDocWord.Document.89q